-transparent.png){kind=logo}
In 9 patients with tachyarrhythmia and atrial fibrillation the effect of the i.v. application of the calcium antagonist Ro 11-1781 on the av-conduction was investigated. All patients received 1 mg/kg during 2-3 minutes. A significant decrease of the ventricular rate at the end of the injection period was noted. The maximal decrease of the av-conduction of 10-32 % of the initial ventricular rate was observed 5-10 min after the injection. During 60 min the initial heart rate before application of the drug was not yet reached again. The registrations prove the inihibiting effect of Ro 11-1781 on av-conduction in atrial fibrillation, which was sufficient for therapeutic use in our cases concerning the reduction of heart rate and duration of the effect. No serious side effects were observed.
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
November 1978,
Bollettino chimico farmaceutico,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
January 1978,
Advances in clinical pharmacology,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
November 1980,
Zeitschrift fur Kardiologie,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
March 1981,
Zeitschrift fur Kardiologie,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
June 1979,
Clinical cardiology,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
January 1979,
European journal of cardiology,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
March 1981,
Zeitschrift fur Kardiologie,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
January 1982,
Journal of cardiovascular pharmacology,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
April 1979,
Clinical cardiology,
B Brisse, and
F Bender, and
H Gülker, and
H Niehues
January 1987,
International journal of clinical pharmacology research,
